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Abstract
Background: The diversity of clinical tumor profiling approaches (small panels to whole exomes with matched or
unmatched germline analysis) may engender uncertainty about their benefits and liabilities, particularly in light of
reported germline false positives in tumor-only profiling and use of global mutational and/or neoantigen data. The
goal of this study was to determine the impact of genomic analysis strategies on error rates and data interpretation
across contexts and ancestries.
Methods: We modeled common tumor profiling modalities—large (n = 300 genes), medium (n = 48 genes), and
small (n = 15 genes) panels—using clinical whole exomes (WES) from 157 patients with lung or colon adenocarcinoma.
We created a tumor-only analysis algorithm to assess germline false positive rates, the impact of patient ancestry on
tumor-only results, and neoantigen detection.
Results: After optimizing a germline filtering strategy, the germline false positive rate with tumor-only large panel
sequencing was 14 % (144/1012 variants). For patients whose tumor-only results underwent molecular pathologist
review (n = 91), 50/54 (93 %) false positives were correctly interpreted as uncertain variants. Increased germline false
positives were observed in tumor-only sequencing of non-European compared with European ancestry patients
(p < 0.001; Fisher’s exact) when basic germline filtering approaches were used; however, the ExAC database
(60,706 germline exomes) mitigated this disparity (p = 0.53). Matched and unmatched large panel mutational
load correlated with WES mutational load (r2 = 0.99 and 0.93, respectively; p < 0.001). Neoantigen load also
correlated (r2 = 0.80; p < 0.001), though WES identified a broader spectrum of neoantigens. Small panels did not
predict mutational or neoantigen load.
Conclusions: Large tumor-only targeted panels are sufficient for most somatic variant identification and
mutational load prediction if paired with expanded germline analysis strategies and molecular pathologist
review. Paired germline sequencing reduced overall false positive mutation calls and WES provided the most
neoantigens. Without patient-matched germline data, large germline databases are needed to minimize false
positive mutation calling and mitigate ethnic disparities.
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Background
The mapping of the human genome, together with the
advent of massively parallel sequencing, has accelerated
discovery of driver genetic alterations in cancer and the
development of drugs to target or otherwise exploit
these events [1]. Multiple tumor profiling approaches
that leverage these advances have entered the clinic.
Such assays often consist of targeted sequencing panels
that query a subset of typically 200–500 genes impli-
cated in cancer biology or clinical management [2–8].
Alternatively, panels that emphasize rapid turnaround
time by profiling smaller gene sets (n = 15–48 genes) have
also emerged [9, 10]. On the other end of the spectrum,
clinical whole-exome sequencing (WES; n ~ 20,000 genes)
of matched tumor and germline samples has been studied
through prospective sequencing efforts [11–13]. However,
the benefits and limitations of these different sequencing
strategies remain incompletely understood.
Understanding the differences in genomic results be-
tween different tumor profiling approaches will become
increasingly important as the cancer genome is lever-
aged to stratify patients for new therapeutic strategies.
For example, unlike targeted therapies linked to specific
genetic lesions (e.g., epidermal growth factor receptor
mutations and inhibitors), immune targeting strategies,
such as checkpoint blockade or personalized cancer
vaccines, may require large-scale ascertainment of muta-
tional and neoantigen loads and individual mutation-
associated neoantigens for personalized cancer vaccine
development [14–18]. One effort demonstrated the
ability of two large gene panels (315 or 573 genes) to
predict mutational load for immunotherapy response
in pilot patient cohorts [19], and another effort dem-
onstrated the ability of one large gene panel (341 genes) to
predict DNA mismatch repair protein deficient tumors
through mutational load [20], although a systematic
characterization of different tumor profiling strategies
for both mutation load and personal neoantigen iden-
tification should inform their relative utilities for
stratifying patients in emerging cancer precision medicine
frameworks.
Moreover, although sequencing of paired normal
blood or tissue samples is standard practice for
research-oriented WES applications, many targeted
panel approaches do not include matched normal
samples [2, 3, 9, 21, 22]. Together with the limited
ancestral diversity in many existing germline data-
bases, this absence of paired normals has raised concerns
for the potential of increased false positive somatic muta-
tion calls that are actually germline [23, 24].
To investigate these issues, we analyzed clinical se-
quencing data from 157 patients with advanced lung and
colon adenocarcinoma to ascertain the relative merits of
distinct tumor profiling approaches.
Methods
Patients and tumor specimens
All patients consented to an institutional review
board-approved protocol that allows comprehensive
genetic analysis of tumor and germline samples
(Dana-Farber Cancer Institute #12-078). Ancestry sta-
tus was self-reported. Samples were selected from
pathology archives by a board-certified anatomic
pathologist based on sample size, tumor purity, and
timing relative to date of study enrollment and ana-
lyzed by the Center for Advanced Molecular Diagnostics
(CAMD) at Brigham and Women’s Hospital (BWH),
a Clinical Laboratory Improvements Amendments
(CLIA)-certified laboratory. Tumor content was esti-
mated by an anatomic pathologist from correspond-
ing stained slides and only samples with at least 20 %
malignant cells were analyzed. DNA was isolated
with a commercial kit (QIAamp DNA Mini Kit,
Qiagen, Valencia, CA, USA) following the manufac-
turer’s instructions. DNA was quantified (PicoGreen,
ThermoFisher Scientific, Waltham, MA, USA) and
samples with at least 50 ng/μL of DNA proceeded to
library preparation.
Whole exome sequencing
WES from formalin-fixed, paraffin embedded (FFPE)
samples was performed as described previously [12].
Whole-exome capture libraries were constructed from
tumor and normal DNA after sample shearing, end re-
pair, phosphorylation, and ligation to barcoded sequen-
cing adaptors. DNA was then subjected to solution-
phase hybrid capture using Agilent baits. The samples
were multiplexed and sequenced using Illumina HiSeq
technology. All BAM files were deposited in dbGap
phs001075.v1.p1.
Genomic analysis
Sequence data processing and quality control
WES data were processed using established analytical pipe-
lines at the Broad Institute [12]. A BAM file was produced
using the Picard pipeline (http://broadinstitute.github.io/
picard/), which aligns tumor and normal sequences to the
hg19 human genome build from raw Illumina reads using
the BWA aligner (version 0.5.9-tpx [0.5.9 with an internal
patch to support threading]). BAM files were uploaded into
the Firehose pipeline (http://www.broadinstitute.org/
cancer/cga/Firehose), which manages input and out-
put files to be executed by GenePattern [25]. Quality
control modules within Firehose were applied to all
sequencing data for comparison of the origin for tumor
and normal genotypes and to assess fingerprinting con-
cordance. Cross-contamination of samples was estimated
using ContEst [26]; those with >5 % contamination were
excluded from subsequent analysis.
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Somatic alterations and downsampling
MuTect (version 1.1.6) [27] was applied to identify som-
atic single-nucleotide variants. Artifacts introduced by
DNA oxidation during sequencing or from FFPE were
computationally removed using a filter-based method
[28]. Annotation of identified variants was done using
Oncotator (version 1.2.7.0) [29]. Representative large
(n = 300) [3], medium (n = 48), and small (n = 15) [9]
gene sets were defined through review of literature
(Additional file 1: Table S1; Additional file 2: Table S2;
Additional file 3: Table S3). The aggregate mutation data
across the whole exome were collected in two files, one
containing all tumor-germline matched calls (Additional
file 4: Table S4) and a second containing tumor-only calls
(Additional file 5: Table S5). “Downsampling” was per-
formed on the aggregate somatic mutation alteration data
files to derive subsets of WES data for gene sets repre-
sented by the large, medium, and small gene lists defined
by the respective panels. For example, to model the 300
gene panel, the set of mutations from the entire WES data
was restricted to only consider events in those 300 genes.
The analyses were performed using the R statistical
software.
Tumor-only and germline analysis
Tumor-normal paired mutation data were taken to be
the set of all true somatic mutations for each patient. To
ensure only high-confidence mutation calls were consid-
ered, only mutations with an allelic fraction ≥5 % and se-
quencing or FFPE artifact filtering strategies described
above were considered. Tumor-only mutation calling
was performed by using MuTect and pairing the tumor
WES with an FFPE germline whole exome from another
patient to reduce false positive calls introduced by ar-
tifacts from the sequencing process, as described pre-
viously [23]. Variants were removed if they were
present in combinations of dbSNP (build 134) [30]
and 1000 Genomes (phase 1, version 3) [31] using
the Oncotator annotation algorithm [29], along with
the ExAC (version 0.3) [32] databases. Mutations were
rescued if listed as somatic in COSMIC (version 74)
at least one, three, five, or ten times, for increasing
stringency [33]. Positive predictive values for each filter
were calculated by dividing the number of true somatic
mutations in the post-filtering mutation data by the total
number of unfiltered mutations. Sensitivity was calculated
by dividing the number of true somatic mutations in the
tumor-only post-filtering data by the total number of
known somatic mutations in the paired mutation data. To
obtain the set of known germline variants, the GATK
HaplotypeCaller (version 3.1.1) [34, 35] was applied to
germline sequence BAMs to identify germline single-
nucleotide polymorphisms (SNPs) using WES data from
each patient. Unfiltered germline variants in tumor-only
targeted panel data after application of various database
filters were identified by comparison with exome germline
SNP data.
Orthogonal large panel molecular pathology review
A subset of cases (n = 91) underwent separate testing
with an academic lab large gene panel (“OncoPanel”),
followed by molecular pathology review [3]. Specifically,
after variants were identified by computational ap-
proaches, an individual molecular pathologist reviewed
each variant and assigned a tier based on clinical action-
ability and to determine whether the variant was likely
somatic or germline and whether there were any clinical
actions for the variant. The four tiers in this system are:
Tier 1 The alteration has well-established published
evidence confirming clinical utility in this tumor
type in at least one of the following contexts:
predicting response to treatment with a US
Food and Drug Administration (FDA)-approved
therapy; assessing prognosis; establishing a
definitive diagnosis; or conferring an inherited
increased risk of cancer to this patient and
family.
Tier 2 The alteration may have clinical utility in at
least one of the following contexts: selection of
an investigational therapy in clinical trials for
this cancer type; limited evidence of prognostic
association; supportive of a specific diagnosis;
proven association of response to treatment
with an FDA-approved therapy in a different
type of cancer; or similar to a different mutation
with a proven association with response to
treatment with an FDA-approved therapy in
this type of cancer.
Tier 3 The alteration is of uncertain clinical utility but
may have a role as suggested by at least one of
the following: demonstration of association with
response to treatment in this cancer type in
preclinical studies (e.g., in vitro studies or
animal models); alteration in a biochemical
pathway that has other known, therapeutically
targetable alterations; alteration in a highly
conserved region of the protein predicted, in
silico, to alter protein function; or selection of
an investigational therapy for a different cancer
type.
Tier 4 The alteration is novel or its significance has not
been studied in cancer.
Mutation rates and neoantigens
The mutation rate for each sample was calculated by
dividing the number of bona fide mutation calls post-
filtering by the total genomic territory sequenced (in
Garofalo et al. Genome Medicine  (2016) 8:79 Page 3 of 10
megabases). Germline exome data from each patient
were used to genotype human leukocyte antigen (HLA)
loci with POLYSOLVER [36]. Patient HLA genotypes
and matched exome mutation data were used as inputs
for NetMHCPan [37] to generate predicted binding af-
finities of somatic mutations linked to specific MHC
class I molecules. Predicted mutation-associated neoan-
tigens were defined as all 9- and 10-amino-acid peptides
resulting from tumor-specific mutations with predicted
HLA binding affinities <500 nM using NetMHCpan
(v2.4). Downsampled panel data were queried for exome
neoantigens to determine the fraction of putative neoan-
tigens observed in WES that were recoverable from
panel mutation calls.
Statistical tests
The sample size was based on available material, and
thus there was not an a priori power calculation. Com-
parisons of germline false positive rates between ancestry
groups was performed with two-sided Fisher’s Exact test.
Pearson correlation tests were performed for mutational
and neoantigen load comparisons in the three panel
settings.
Results
Reducing false-positive germline variants in tumor-only
analysis
The study included 157 patients, who underwent clinical
sequencing: 75 with colorectal adenocarcinoma and 82
with lung adenocarcinoma. Clinical tumor and germline
WES [12] produced a mean coverage of 154× and 133×
in tumor and normal DNA, respectively (Additional file 6:
Table S6). The combination of sequencing depth and
tumor purity (“Methods”) enabled mutation detection in
these cases. Large (n = 300) [3], medium (n = 48), and
small (n = 15) [9] gene panel data were produced by
creating subsets of the whole exome mutation data
(“downsampling”) to simultaneously model the different
gene sets captured in multiple representative academic
and commercial efforts. Matched tumor–germline se-
quencing revealed a median of 75 (interquartile range of
first and third quartiles [IQR] = 55–134), 4 (IQR = 3–6), 2
(IQR = 1–3), and 1 (IQR = 1–2) mutations per patient for
WES, large, medium, and small panels, respectively. Un-
matched tumor-only sequencing produced a median of
445 (IQR = 404–531), 10 (IQR = 8–13), 3 (IQR = 2–5), and
2 (IQR = 1–2) mutations per patient. Thus, the proportion
of putative somatic variants was increased in tumor-only
sequencing data under all conditions.
For all targeted panel options, both sensitivity and
positive predictive value (PPV) could be optimized by
using an analytical pipeline that consisted of an un-
matched germline sample, the largest publically available
germline WES database (ExAC) [32], and recovery of
somatic mutations with COSMIC at the highest fre-
quency threshold (n ≥ 10 events) to recover mutational
hotspots [38] (Fig. 1a, b; “Methods”; Additional file 7:
Table S7). For large tumor-only targeted panels, this fil-
tering led to 14 % (144/1012 variants) of putative som-
atic mutations that were actually germline false positive
variants (Fig 1c). For unmatched WES, the germline
false positive rate with this approach was even higher
(18 %; 5282/29,738 variants).
A subset of these cases (n = 91) underwent orthogonal
molecular pathologist review of variants (“Methods”).
The addition of pathologist review after in silico analysis
resulted in 50/54 (93 %) false positives interpreted as un-
known variants (tier 4) that may be germline false posi-
tives rather than somatic alterations (Fig. 1c, d). Of the
four remaining germline false positive results, three
(RB1 K874Q, MSH6 S405C, BRCA2 splice site mutation
at the junction of exons 2 and 3 (g.32890665G > A))
were classified as uncertain clinical utility and only one,
a known pathogenic variant associated with hereditary
cancer syndromes (TP53 R248Q), was classified as hav-
ing potential clinical utility based on negative prognostic
implications (Fig. 1d).
The impact of ancestry on germline false positives in
tumor-only analysis
The use of germline databases is a critical component
for removing false positive germline calls in tumor-only
panel sequencing (“Methods”); however, the representa-
tion of non-European ancestry in these databases is in-
complete [39]. Therefore, we next sought to measure the
variation in false positive rates in populations with dif-
ferent self-reported ancestries. When the dbSNP data-
base was used as a filter in large panel tumor profiling
analysis [30], germline false positives were significantly
increased in tumor-only sequencing of non-European
compared with European ancestry patients (odds ratio
[OR] = 2.52, p < 0.001; Fisher’s exact; Fig. 2a). While the
median number of false positives among the two popula-
tions was the same (n = 2), 32 % (6/19) of non-white
patients had more than five false positives, whereas 5 %
(7/132) of white patients had more than five germline
false positives.. A similar relationship was observed with
the use of 1000 Genomes (OR = 1.83, p < 0.001; Fisher’s
exact; Fig. 2b). However, use of ExAC [32], a public
database of 60,706 germline exomes that represents
an order-of-magnitude increase in germline variant
data compared with other databases, mitigated this
disparity (OR = 1.19, p = 0.53; Fig. 2c). Therefore,
tumor-only mutational profiles require the use of
germline databases with sufficiently broad representa-
tion to minimize the elevations in false positives that
might otherwise be seen in patients with diverse eth-
nic backgrounds.
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Impact of gene panel size on mutational load and
neoantigen prediction
Given the potential utility for immuno-oncology patient
stratification, we next investigated the extent to which
various tumor profiling platforms might inform genome-
wide properties. First, we explored whether mutational
loads measured directly (using paired WES data) corre-
lated with mutational loads inferred from targeted panel
data (e.g., <2 % of the genomic territory covered by
WES). To test this, we divided the number of mutations
observed in the panel by the genomic territory covered
(in megabases) by that panel (“Methods”). Consistent
with previous reports [19], we found that large-panel
mutational loads correlated strongly with WES-based
mutational load regardless of whether tumor-only or
paired data were used (r2 = 0.99 for matched and 0.93
a
c
b
d
Fig. 1 Germline false positives in tumor-only clinical sequencing. Sensitivity and positive predictive value (PPV) curves for multiple germline filtering
strategies identifies optimal approaches for unmatched large targeted panel testing (a) and whole-exome sequencing (b). For 91 patients, germline
exome data were used to identify false positives post-filtering. Subsequent molecular pathologist review of variants was performed on individual cases
to further classify putative germline variants. With molecular pathology review, 50/54 false positive variants were correctly classified as unknown
(“tier 4”), with the remaining variants classified as having uncertain (n = 3; “tier 3”) or potential (n = 1; “tier 2”) clinical utility (c, d). Please see
“Methods” for detailed descriptions of the four-tier classification schema
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Fig. 2 Ancestry and germline false positives using different analysis strategies. a The use of dbSNP as the primary germline filtration
strategy results in a significant increase in false positives among non-white patients (p < 0.001). b A similar increase was observed with
the use of 1000 Genomes (p < 0.001). c With larger germline databases such as ExAC, this disparity is mitigated
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for unmatched; p < 0.001), with median nonsynon-
ymous mutation rates of 2.3/Mb (IQR = 1.7–4.2) and
5.5/Mb (IQR = 4.1–8.2) in WES and panels, respect-
ively (Fig. 3a, b). The ability of medium gene panels
to predict the WES mutational load was somewhat re-
duced (r2 = 0.84 and 0.71, respectively). Small panels were
poor predictors of overall mutational load (0.4 < r2 ≤ 0.6
for all conditions). When analyzed separately, the lung
and colon cancer subsets achieved comparable results
across the three settings (Additional file 8: Figure S1;
Additional file 9: Figure S2). Thus, large matched or
unmatched panels successfully recapitulated the WES
mutational load.
Given the potential importance of identifying patient-
specific neoantigens—novel protein sequences absent
from the normal human genome that arise from somatic
mutations [40]—for immuno-oncology applications
[16–18, 41], we sought to identify neoantigens derived
from the different panels and WES. To do this, we
integrated patient human leukocyte antigen (HLA)
typing [42] with the set of all potential neoantigens to
identify those with predicted high affinities to the pa-
tient’s MHC class I alleles (“Methods”). The median
neoantigen load across all patients as determined by
WES data was 38 neoantigens per exome, while the
median number of those called by large panel targeted se-
quencing was one neoantigen per panel (Fig. 4a). The me-
dian number of neoantigens called in both small and
medium panels was zero. No correlation was discovered
between small/medium panel neoantigen calls and exome
neoantigen calls (r2 = 0.24 and r2 = 0.62, respectively);
however, we did observe a correlation between large panel
neoantigen and exome neoantigens (r2 = 0.81) (Fig. 4b–d).
In the WES data, 5511 neoantigens with binding affinities
of <500 nM were identified across the 157 patient
samples. Of these, 229 (4.1 %) were observed through
matched targeted panel sequencing data (Fig. 4a). Thus,
while large panels were able to recapitulate mutation and
predicted neoantigen loads, most potentially immuno-
genic neoantigens occurred in genes that were not repre-
sented in these cancer panels and would not be
observable for cancer vaccine strategies.
a
b
Fig. 3 Mutational load predictions with different panel tests. Comparison of mutational load predictions using WES or either matched (a) or
unmatched (b) large panel tests (n = 300 genes) demonstrates both can reliably predict the mutational load. The linear regression line is shown in
black with 95 % confidence bands shaded in grey. The identity line (dashed) is shown for comparison. With medium sized panels (n = 48 genes),
this ability decreases in both the matched and unmatched setting and is not possible with small (n = 15) gene panels
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Discussion
As precision medicine efforts proliferate in clinical on-
cology settings, a spectrum of tumor gene profiling
strategies—from individual variant testing to compre-
hensive WES—are being utilized. We sought to assess
the relative merits of each by analyzing genomic data
from 157 lung and colon adenocarcinoma cases,
followed by in silico modeling of different forms of tar-
geted panel testing to determine their analytical
strengths and weaknesses.
One priority was to determine best practices for germ-
line filtering in the setting of tumor-only profiling. While
our results identified a consistent (albeit lower) rate of
germline false positive findings when leveraging large,
publically available germline variant data sets, we found
that the addition of molecular pathologist review was
highly effective in reducing false positive errors germane
to unmatched sequencing. This observation may be in-
formative in centers where assembling a molecular
tumor board may not be practically feasible but individ-
ual molecular pathologists can act as reviewers.
Even so, the higher false positive germline variants in
non-white ancestries highlights the limitations of utiliz-
ing germline genomic databases for such filtering, as
these cohorts may not represent the clinical population
being tested. Tumor-only analytical pipelines that do not
anticipate diverse ancestry could unwittingly produce a
higher rate of germline false positives in some ancestral
backgrounds. Expansion of germline databases to repre-
sent the diversity of patients tested is necessary to miti-
gate this source of false positives, and this strategy may
contribute to the improvement of precision medicine
health disparities resulting from analytical features of the
human genome. Indeed, as clinical genomic profiling
becomes increasingly expansive technologically, with
whole-genome and whole-transcriptome sequencing be-
ing performed in clinical settings, the need to capture a
diverse set of patients is especially relevant.
Furthermore, because of the emerging therapeutic ave-
nues associated with tumor neoantigens and mutational
load, we sought to analyze the ability of targeted panels
to identify patients who might benefit from such
a
b c d
Fig. 4 Neoantigen predictions in panels. a The proportion of neoantigens called in large panel targeted sequencing data demonstrates an
inability to identify as a broad spectrum of neoantigens compared to WES. b Nonetheless, there is a linear relationship between large panel
neoantigens recovered from exome and germline-matched large panel data. This linear relationship no longer holds when considering neoantigen
data from medium (c) and small (d) targeted panels
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treatments. Indeed, targeted large panel mutation rate
approximated the WES mutation rate well for most
samples, whether the targeted panel was matched or un-
matched. This suggests that large targeted panels may be
useful for flagging patients with exceptionally high muta-
tion rates for specific clinical investigations. Yet, targeted
panel sequencing results failed to recapitulate the neoan-
tigen load estimated from WES data, which may be as
relevant as mutational load data when combined with
immunohistochemistry markers (i.e., PD-L1 staining) to
stratify patients for immunotherapies [43].
In addition, since only a small fraction of total neoan-
tigens fell within the genomic regions covered by the
targeted panel (average tumor sample had less than
three neoantigens called in the targeted sequencing
data), it is likely impossible to stratify patients based on
relative neoantigen loads from targeted sequencing data
alone. Also, the targeted panel does not call most of the
patient-specific neoantigens themselves, which may be-
come increasingly relevant as personalized cancer vaccine
strategies requiring knowledge of specific neoantigens ex-
pand across many clinical settings [44–47].
The main limitation of this study is that, due to the
rapidly expanding diversity of panel-based sequencing
approaches offered in commercial and academic labs, it
was not possible to directly and comprehensively com-
pare outputs of all available approaches with these clin-
ical samples. As a result, certain components of the
workflow could not be examined in this context, such as
the impact of higher sequencing depth on variant detec-
tion sensitivity [8] or the differences in germline false
positive results from different lab analysis processes.
Indeed, since not all labs report specific details about
analysis methods, such as how exactly germline variants
are filtered, we could not confirm whether the approach
outlined in this effort is consistent across vendors. This
highlights the importance of encouraging transparency
in analytical efforts given how widely variable results
may seem depending on which approach is used. Since
germline variants may also have immediate clinical im-
plications for assigning cancer risk [48] and therapeutic
strategies [49], distinguishing somatic and germline
events is especially relevant in this context. Furthermore,
this study highlights certain benefits of WES, although
WES compared with panel testing has additional costs
(i.e., financial, interpretive) beyond analytical.
Conclusions
Broadly, our work highlights the relative advantages and
disadvantages of WES and targeted panel sequencing for
clinical precision oncology. Targeted panel sequencing
maintains an advantage over WES for variant identifica-
tion in a small set of known clinically informative cancer
genes and utilization of germline enhances somatic
mutation identification. Additionally, prior studies have
demonstrated that targeted panels enable more sequen-
cing depth compared with WES. Since the WES ob-
tained for this study was considered sufficient to enable
the subsequent analyses, this technical component of
targeted panels did not require further exploration to
enable the studies described herein.
Even so, the breadth and adaptability of WES may ul-
timately offer advantages over targeted panels for certain
immunotherapy regimens. As treatment paradigms shift
and require detailed assessments of global genomic
changes for immunotherapy purposes, as well as deep
clonal architecture of tumors feasibly enabled through
deeper targeted sequencing, a combination of these
strategies may prove most effective for genomic analysis
in the clinic. When paired with up-to-date bioinformat-
ics and database filtering, along with molecular path-
ology assessment, this strategy may inform wider
analytical standardization for genomic analysis.
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